# OnCo record pd1 (target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/targets/pd1/>
  a schema:BioChemEntity ;
  onco:kind "target" ;
  schema:identifier "pd1" ;
  schema:name "PD-1"@en ;
  schema:description "PD-1 is a brake on T cells. Blocking it releases the immune system against the tumour and has cured some previously incurable cancers."@en ;
  schema:url <https://onco.cc/targets/pd1/> ;
  schema:dateModified "2026-09-04"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Programmed_cell_death_protein_1>, <https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:8760>, <https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000188389>, <https://www.uniprot.org/uniprotkb/Q15116/entry>, <https://www.ncbi.nlm.nih.gov/gene/5133> ;
  owl:sameAs <http://www.wikidata.org/entity/Q21208025> ;
  schema:citation <https://en.wikipedia.org/wiki/Programmed_cell_death_protein_1> ;
  onco:tag "checkpoint" ;
  schema:alternateName "PDCD1" ;
  onco:targetClass "checkpoint" ;
  onco:firstDescribed "1994"^^xsd:gYear ;
  onco:cancers <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/rcc/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/colorectal/> ;
  onco:drugs <https://onco.cc/drugs/tqb2450/>, <https://onco.cc/drugs/bcd-217/>, <https://onco.cc/drugs/tak-928/>, <https://onco.cc/drugs/sasanlimab/>, <https://onco.cc/drugs/ibi363/>, <https://onco.cc/drugs/t3011/>, <https://onco.cc/drugs/ssgj-705/>, <https://onco.cc/drugs/ssgj-706/>, <https://onco.cc/drugs/rilvegostomig/>, <https://onco.cc/drugs/lorigerlimab/>, <https://onco.cc/drugs/ai-081/>, <https://onco.cc/drugs/gc101-til/>, <https://onco.cc/drugs/azd7789/>, <https://onco.cc/drugs/lb1410/> ;
  onco:companies <https://onco.cc/companies/cofactor-genomics/>, <https://onco.cc/companies/compass-therapeutics/>, <https://onco.cc/companies/insight-molecular-diagnostics/>, <https://onco.cc/companies/onc-ai/>, <https://onco.cc/companies/oncohost/>, <https://onco.cc/companies/ose-immunotherapeutics/>, <https://onco.cc/companies/xilio-therapeutics/> ;
  onco:pathways <https://onco.cc/pathways/pd1-checkpoint/>, <https://onco.cc/pathways/t-cell-exhaustion/> ;
  onco:trials <https://onco.cc/trials/nct06631092/>, <https://onco.cc/trials/nct07266428/>, <https://onco.cc/trials/nct06492005/>, <https://onco.cc/trials/nct06144671/>, <https://onco.cc/trials/nct06244992/>, <https://onco.cc/trials/nct06107374/>, <https://onco.cc/trials/nct06631079/>, <https://onco.cc/trials/nct05023486/>, <https://onco.cc/trials/nct05838729/>, <https://onco.cc/trials/nct07444437/>, <https://onco.cc/trials/nct07293754/> .